Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, phase 3 IDHENTIFY trial Meeting Abstract
| Authors: | DiNardo, C. D.; de Botton, S.; Risueño, A.; Schuh, A. C.; Lowenberg, B.; Kim, H. J.; Vyas, P.; Wei, A. H.; Stein, E. M.; Döhner, H.; Fathi, A. T.; Martin-Regueira, P.; Taningco, L.; Bluemmert, I.; Yu, X.; See, W. L.; Hasan, M. |
| Abstract Title: | Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, phase 3 IDHENTIFY trial |
| Meeting Title: | 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | biomarkers; aml; relapsed/refractory; phase iii; idh2; enasidenib |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Sep 28-Oct 1 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S249 |
| End Page: | S250 |
| Language: | English |
| ACCESSION: | WOS:000897948100172 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(22)01293-9 |
| Notes: | Meeting Abstract: AML-432 -- Source: Wos |
